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The molecular immunopathogenesis of West Nile virus (WNV) infection is poorly understood. 
Here, we characterize a mouse model for WNV using a subcutaneous route of infection and 
delineate leukocyte subsets and immunoregulatory factors present in the brains of infected 
mice. Central nervous system (CNS) expression of the chemokine receptor CCR5 and its ligand 
CCL5 was prominently up-regulated by WNV, and this was associated with CNS infiltration of 
CD4
 
 
 
 and CD8
 
 
 
 T cells, NK1.1
 
 
 
 cells and macrophages expressing the receptor. The significance 
of CCR5 in pathogenesis was established by mortality studies in which infection of CCR5
 
 
 
/
 
 
 
 
mice was rapidly and uniformly fatal. In the brain, WNV-infected CCR5
 
 
 
/
 
 
 
 mice had increased 
viral burden but markedly reduced NK1.1
 
 
 
 cells, macrophages, and CD4
 
 
 
 and CD8
 
 
 
 T cells 
compared with WNV-infected CCR5
 
 
 
/
 
 
 
 mice. Adoptive transfer of splenocytes from WNV-
infected CCR5
 
 
 
/
 
 
 
 mice into infected CCR5
 
 
 
/
 
 
 
 mice increased leukocyte accumulation in the 
CNS compared with transfer of splenocytes from infected CCR5
 
 
 
/
 
 
 
 mice into infected CCR5
 
 
 
/
 
 
 
 
mice, and increased survival to 60%, the same as in infected CCR5
 
 
 
/
 
 
 
 control mice. We conclude 
that CCR5 is a critical antiviral and survival determinant in WNV infection of mice that acts 
by regulating trafficking of leukocytes to the infected brain.
 
West Nile virus (WNV) is an enveloped, neu-
rotropic, single stranded (
 
 
 
) sense RNA
flavivirus, first isolated from a woman in
Uganda in 1937 (1). Since then it has reemerged
multiple times: first in Europe, and most recently
during the summer of 1999 in the northeastern
United States (2, 3). The virus, which has
spread rapidly throughout North America,
may cause severe illness especially in the elderly
(manifested by meningitis and encephalitis)
that may lead to paralysis, coma, and death.
During the 1999–2003 outbreaks of WNV in
the USA, 13,491 cases were reported, including
533 deaths (
 
 
 
4%) (3, 4).
A zoonosis, WNV is maintained in a natural
cycle between avian hosts and mosquito vectors,
although humans, horses, and several other
mammals can also serve as hosts (5–8). The
level of exposure required for infection and
disease is undefined; however, epidemiologic
studies indicate that 
 
 
 
80% of WNV infection
remains subclinical whereas 
 
 
 
20% progresses
to a febrile illness. Of these, 
 
 
 
30% of cases in the
US progress to meningitis and/or encephalitis.
Survivors of severe neurological disease typically
require prolonged rehabilitation. There is no
vaccine or specific antiviral treatment for WNV
infection in humans.
Although immunocompromised hosts appear
to have increased susceptibility to WNV, specific
information on the human innate and adaptive
cellular immune response to the virus is limited
(2, 9–11). Several mouse models of infection that
differ with regard to mouse and viral strain, route
of infection, and clinical outcome have been
developed to provide insight into immunopatho-
genesis (12–15). We have used a model in which
the highly neurotropic and neurovirulent WNV-
NY99 strain is injected s.c., resulting in viral
replication  and leukocyte infiltration in the
brain 4–7 d after infection (13, 16–19). A
variant of this model has been used previously
to demonstrate that both B and T cells are re-
quired for viral clearance, because 100% of both
RAG1
 
 
 
/
 
 
 
 mice and 
 
 
 
MT
 
 
 
/
 
 
 
 mice rapidly
succumb to viral infection, whereas only 
 
 
 
35%
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of mice with intact immune systems die (19, 20). The
primary role of humoral immunity is thought to limit
viral dissemination to the central nervous system (CNS).
CD8
 
 
 
 T cells play a prominent role in viral clearance
from the CNS, as infected CD8
 
 
 
/
 
 
 
 mice have increased
mortality (
 
 
 
85%) and higher CNS viral burden and viral
persistence (13).
Encephalitis caused by other neurotropic/neurovirulent
viruses is often characterized by CNS entry of macrophages,
CD4
 
 
 
 and CD8
 
 
 
 T cells, NKT cells and dendritic cells.
However, little information is available regarding the molec-
ular factors responsible for their recruitment. Here, we pro-
vide a profile of the leukocyte subsets and proinflammatory
and immunoregulatory molecules present in the CNS of
Figure 1. West Nile virus induces production of specific immuno-
regulatory factors in the brains of C57BL/6 mice. (A) RNA analysis by 
RPA. Leftmost lane in each of the four panels is unprotected probe, and 
the factors analyzed are named to the left; note that the protected fragments 
run slightly lower on gel. The names of factors scoring positive in the assay 
are given to the right of each band. GAPDH is provided as an RNA loading 
control. Time after infection (days), is indicated at the top of each panel. 
Mock-infected mice were analyzed on day 7 of the experiment. Each lane 
on each panel corresponds to RNA from a single mouse brain. The results 
shown are from two independent experiments with six mice analyzed 
for each time point, except for mock-infected mice (n   3). Lanes 
corresponding in location on each of the four gels represent RNA from 
the same mouse. (B) RNA analysis by RT-PCR.  -Actin is provided as a loading 
control. Mock-infected mice were analyzed at day 7. Each lane represents 
a single mouse. (C) Protein analysis. The factor analyzed is identified at 
the top left of each graph. Time and virus variables for each factor are 
specified at the bottom of the panel. Data were pooled from three 
experiments with three to five in each group, and are presented as
mean   SEM pg/g protein in supernatants from total brain homogenates 
as a function of time after infection. 
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WNV-infected mice. We have used this profile to identify
the chemokine receptor CCR5 as a candidate protective fac-
tor, and have tested this hypothesis genetically using CCR5
knockout mice.
 
RESULTS
 
C57BL/6 mice were infected s.c. with 10
 
0
 
–10
 
6
 
 focus-forming
units (ffu) of strain WNV-NY99, which imitates the natural
route of WNV infection in man. All mice infected with 1 or 10
ffu survived. Mortality was first observed in animals injected
with 100 ffu and was 30% at that dose (unpublished data). Mor-
tality was relatively insensitive to further increases in WNV
dose reaching only 40% at 10
 
6
 
 ffu, the highest dose tested. This
is consistent with previously published data for WNV-NY99
infection of this strain of mice using a footpad injection (19).
Based on these results, we infected mice with 10
 
4
 
 ffu WNV s.c.
for all subsequent studies. Using this dose, all deaths occurred
between 7 and 12 d after infection.
 
WNV infection induces immunoregulatory mediators 
in the CNS
 
To identify molecules that might be important in WNV en-
cephalitis, we screened a total of 45 different immunoregula-
tory factors for differential expression in the brains of mock-
and WNV-infected mice on days 7 and 12 after infection.
Of these, 37 (9 cytokines, 8 cytokine receptors, 11 chemo-
kines, and 9 chemokine receptors) were screened at the
RNA level by either RPA or RT-PCR of mouse brain (Fig.
1, A and B) and positive samples were quantified using
GAPDH or 
 
 
 
-actin signals for normalization. Although
there was some variability in expression among the mice
tested, we accepted as candidates those factors for which ex-
pression was increased in at least one mouse. 13 of these fac-
tors were expressed in a WNV-dependent manner. 8 out of
the 13 (IFN
 
 
 
, IL-12 receptor 
 
 
 
1 and the chemokines
CXCL10, MIP-2, CCL2, CCL3, CCL4, and CCL5) were
not detected in the brains of mock-infected mice, but were
induced specifically by WNV; the other 5 were all chemo-
kine receptors (CCR1, CCR2, CCR5, CXCR3, CX
 
3
 
CR1)
and were constitutively expressed in mock-infected mouse
brains but were further induced by WNV. 12 out of these
13 factors typically are associated with Th1 immune re-
sponses. The major Th2 cytokines IL-4, IL-5, and IL-13
were not detected in the brains from either mock- or virus-
infected animals. Thus, WNV appears to generate a Th1
cell–polarized immune response in this model. We identified
10 other factors constitutively expressed at the RNA level
that were not further induced by WNV (IL-10 and its recep-
tor; IL-15; IL-11 receptor; gp130; 
 
 
 
 and 
 
 
 
 chains of the
IFN-
 
 
 
 receptor; the chemokines CXCL4 and CX
 
3
 
CL1; and
the chemokine receptor CXCR4).
Nine of the factors up-regulated at the RNA level were
also tested at the protein level and were positive (Fig. 1 C).
Of these, seven were factors induced by WNV (IFN-
 
 
 
 and
the chemokines CCL2–5, MIP-2, and CXCL10). CCL5
was particularly strongly and durably induced. We screened
an additional seven factors in the brain at the protein level
and found that all were highly induced by WNV. Three of
the seven—IFN-
 
 
 
, TNF-
 
 
 
 and CXCL9—were not consti-
tutively detected. IFN-
 
 
 
 and TNF-
 
 
 
 expression was tran-
Figure 2. West Nile virus induces multifocal encephalitis in C57BL/6 
mice. (A) Histologic analysis. Brains of mock- and WNV-infected CCR5 /  
and CCR5 /  mice harvested at day 12 after infection were fixed in formalin 
and embedded in paraffin. Coronal sections 6- m thick were stained with 
hematoxylin and eosin to visualize cells and luxol fast blue to stain myelin 
tracts blue. Multiple cellular infiltrates were observed in the infected mice 
(circled in the 10  image). Typical infiltrates are shown at higher 
magnification in the hippocampus (arrows). GrDG, granule cell layer of the 
dentate gyrus. (B) Immunohistochemical analysis. Brain sections, prepared 
as in A from mock- and WNV-infected mice with the indicated CCR5 
genotype, were stained with methyl green and anti–human CD3 mAb. 
Representative sections of the cortex are shown. CD3  cells stain brown. 
Images in A and B are representative of five mock-infected brains, nine 
WNV-infected CCR5 /  brains, and six WNV-infected CCR5 /  brains. 
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sient, with large amounts of cytokine found on day 7 after
infection, but not on day 12. Constitutive expression of the
other four factors (IL-1
 
 
 
, the adhesion molecule ICAM-1,
and the metalloproteinase MMP-9 and its inhibitor TIMP-1)
was markedly increased by virus and remained elevated
throughout the 12 d period of observation. These molecules
may serve to arrest activated leukocytes in cerebral blood
vessels and break down the blood brain barrier to facilitate
leukocyte penetration into infected brain tissue. With regard
to candidate leukocyte chemotactic systems that might guide
this process, our data point clearly to the non-ELR CXC
chemokines CXCL9 and CXCL10 and their receptor
CXCR3; and the CC chemokines CCL2, CCL3, CCL4,
and CCL5 and their receptors CCR1, CCR2, and CCR5.
The RNA data suggest that the CX
 
3
 
C chemokine CX
 
3
 
CL1
and its receptor CX
 
3
 
CR1 may also play a role. For the re-
mainder of this paper, we focus our analysis on the role of
CCR5 in WNV pathogenesis.
 
CCR5
 
 
 
 leukocytes accumulate in WNV-infected mouse brain
 
We examined histopathological sections of mock- and
WNV-infected mice and visualized intense multifocal cellu-
lar infiltrates, primarily localized to hippocampus and exter-
nal capsule, evident in WNV-infected but not mock-
infected mouse brain stained either by hematoxylin and
eosin or anti-CD3 (Fig. 2, A and B). Previously published
work (21, 22), confirmed by us (unpublished data), has
shown that WNV infects neurons.
Consistent with the histological analysis and immunohis-
tochemistry results, we observed a notable increase in leuko-
cytes isolated from WNV-infected wild-type mouse brains at
both 7 and 12 d after infection (Figs. 3 and 4). The total
amount of CD4
 
 
 
 T cells rose from 1.2 
 
 
 
 10
 
3
 
/brain (0.2% of
total leukocytes) in mock-infected brains to 2 
 
  
 
10
 
4
 
/brain
(1.8% of total leukocytes) and 9.6 
 
 
 
 10
 
4
 
/brain (5.0% of total
leukocytes) on days 7 and 12 after infection, respectively.
The amount of CD8
 
 
 
 T cells rose from 1.8 
 
 
 
 10
 
3
 
/brain
(0.3% of total leukocytes) in mock-infected brains to 2.3 
 
 
 
10
 
4
 
/brain (2.0% of total leukocytes) and 1.0 
 
 
 
 10
 
5
 
/brain
(5.3% of total leukocytes) on days 7 and 12 after infection,
respectively. The number of NK1.1
 
 
 
 cells increased from
1.4 
 
 
 
 10
 
3
 
/brain (0.3% of total leukocytes) in mock-infected
brains to 2.2 
 
 
 
 10
 
4
 
/brain (1.9% of total leukocytes) and 4.1 
 
 
 
10
 
4
 
/brain (2.1% of total leukocytes) on days 7 and 12 after
Figure 3. WNV induces accumulation of leukocytes in mouse brain. 
Representative FACS analysis dot plots of mock- and WNV-infected 
CCR5 /  and CCR5 /  mice. Percentages are calculated based on total 
events; histograms to the right of the corresponding dot plot show CCR5 
staining within single positive CD4  or CD8  T cells, NK cells, and the 
three F4/80 /CD45  subsets. The blue line in the histogram represents 
isotype control staining, and the red shaded line represents CCR5 staining. 
Bar shows which portion of the histogram was considered CCR5 positive. 
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infection, respectively. The amount of resident microglia
(F4/80
 
 
 
/CD45
 
lo) remained relatively constant throughout
the course of disease. However, activated resident microglia
(F4/80 /CD45med) rose from a baseline of 0.24   105/brain
(4.4% of total leukocytes) in mock-infected brains to 1.2  
105 (11.0% of total leukocytes) and 2.2   105 (11.1% of total
leukocytes) on days 7 and 12 after infection, respectively.
The most impressive increase was seen in infiltrating mac-
rophages (F4/80 /CD45hi). Mock-infected mouse brains
had only 7.3   103/brain (1.3% of total leukocytes) of these
cells, whereas the amount in infected brains increased to
2.7   105/brain (23.0% of total leukocytes) and 5.5   105/
brain (28.3% of total leukocytes) on days 7 and 12 after in-
fection, respectively (Figs. 3 and 4).
CCR5 has been reported to be expressed mainly on sub-
sets of monocytes, macrophages, NK cells, and T lympho-
cytes. Consistent with this, on day 7 after infection, 12% of
CD8  T cells, and 25% each of CD4  T cells, NK1.1  NK
cells, and F4/80  CD45hi activated infiltrating macrophages,
which were induced to accumulate in the brain by WNV,
expressed CCR5 (Figs. 3 and 4 A). On day 12 after infec-
tion, expression of CCR5 on NK cells and activated mac-
rophages in WNV-infected CNS had decreased to 16% and
15%, respectively, whereas expression on CD4  and CD8 
T cells was not statistically significantly different from ex-
pression on day 7. In mock-infected mouse brain, of the few
leukocytes present, 4% of resident microglial cells (F4/80 /
CD45lo) expressed CCR5 (Fig. 3 and 4 A). Together, these
data support the hypothesis that CCR5 may play a role in
the migration of a portion of CD4  and CD8  T cells, NK
cells and activated tissue-infiltrating macrophages to brains
infected with WNV.
Loss of CCR5 results in impaired leukocyte trafficking 
to the CNS
We tested this hypothesis by comparing the outcomes of
WNV infection between CCR5 /  and CCR5 /  mice.
On day 12 after infection, CCR5 /  mice had markedly re-
duced cellular infiltrates ( 1 lesion per 200  hpf in coronal
sections of the hippocampus and external capsule compared
with 5–8 lesions per 200  hpf for WNV-infected wild type
mice (Fig. 2 A). This was confirmed by direct immunohis-
tochemical analysis of the T cell antigen CD3, which re-
vealed markedly decreased staining of infected CCR5 / 
mouse brains compared with the brains of infected CCR5 / 
mice (Fig. 2 B). FACS analysis allowed for direct quantitation
of this decrease (Figs. 3 and 4). Specifically, on day 7 in
CCR5 /  mice, we found a  50% decrease in the number
of CD4  T cells, NK1.1  cells, F4/80 /CD45med activated
microglia and F4/80 /CD45hi infiltrating macrophages com-
pared with values for WNV-infected CCR5 /  controls.
The number of CD8  T cells was not significantly decreased
at this time point. By day 12 after infection, the reduction in
the cell infiltrate to the WNV-infected CCR5 /  mouse
brain was even more evident: 60% reduction in CD4  T
cells, 46% reduction in CD8  T cells, 84% reduction in
NK1.1  cells, 63% reduction in activated microglia, and a
76% reduction in infiltrating macrophages compared with
infected CCR5 /  control mice (Figs. 3 and 4).
Figure 4. CCR5 regulates accumulation of T cells, NK cells, and 
macrophages in the WNV-infected mouse brain. (A) WNV induces 
accumulation of CCR5  leukocytes in the mouse brain. CCR5 surface 
expression was examined on specific leukocyte subsets isolated from mouse 
brain and the percent positive cells was determined. (B and C) Lack of CCR5 
blunts leukocyte accumulation in the mouse brain in response to WNV 
infection. Data were pooled from three experiments, with three to five mice 
analyzed at each time point/experiment and are presented as the mean   
SEM. *, P   0.04 for the indicated comparison by Student’s t test.CCR5 AND WEST NILE VIRUS PATHOGENESIS | Glass et al. 1092
To determine whether reduced leukocyte accumula-
tion in the brain could be attributed indirectly to the loss of
inflammatory mediator expression in CCR5 /  mice, we
measured the effect of CCR5 gene inactivation on the ex-
pression of these molecules in the WNV-infected brain.
No significant differences were found for CCL3, CCL4,
CCL5, MIP-2, CXCL9 or CXCL10 (Tables I and II). On
day 12, the protein levels of the CCR2 ligand CCL2 were
decreased by  50% in brains of CCR5 /  mice infected
with WNV as compared with infected CCR5 /  mouse
brain; however, CCL2 was still expressed at high levels,
 2.5 ng/g brain tissue. We also did not detect CCR5-
dependent differences in the expression of the cytokines
IFN- , IFN- , TNF- , or IL-1  or the adhesion mole-
cule ICAM-1 in WNV-infected mouse brain. There was a
notably lower expression of the metalloproteinase inhibitor
TIMP-1 (but not MMP-9) on day 12 after infection in
WNV-infected CCR5 /  mouse brains compared with in-
fected CCR5 /  controls. However, the blood brain bar-
rier was clearly already compromised by day 12, as evi-
denced by viral burden and leukocyte accumulation in the
CNS by day 7 after infection. Furthermore, the serum lev-
els of TNF- , IFN- , IL-4, IL-5, IL-2, CCL5 and
CXCL10 were not significantly different between WNV-
infected CCR5 /  and CCR5 /  mice throughout the
course of the experiment (Fig. 5 A, P   0.02).
To determine whether the diminished cell accumulation
seen in the CNS of WNV-infected CCR5 /  mice could
be the result of an altered splenic response to the virus, we
directly compared the number of IFN- –producing CD4 
and CD8  T cells from spleens of CCR5 /  and CCR5 / 
mice ex vivo both with and without exogenous stimulation
at several time points after infection. The numbers and per-
centage of CD4 /IFN-   as well as CD8 /IFN-   cells
were nearly identical between the two groups at days 3, 5,
and 7 after infection when no exogenous stimulation was
applied; this result suggests that both groups of mice have the
same splenic immune response to WNV infection (Fig. 5 B).
When splenocytes were stimulated ex vivo with PMA and
ionomycin, the IFN-  response was similar for CCR5 / 
and CCR5 /  mice infected with WNV (Fig. 5 C).
To more directly determine whether defective traffick-
ing of the cells to the CNS is the cause of the cell deficit seen
in WNV-infected CCR5 /  mouse brains, we adoptively
transferred splenocytes from WNV-infected CCR5 /  do-
nor mice intravenously into WNV-infected CCR5 /  re-
cipients and compared cell accumulation in the CNS to
CCR5 /  recipients of the same number of splenocytes
Table I. Effect of CCR5 inactivation on induction of chemokines in the brain by WNV
DAI Infection Strain CCL2 CCL3 CCL4 CCL5 CCL11 CXCL9 CXCL10
7 mock CCR5 /  BLD BLD BLD BLD BLD BLD BLD
7 mock CCR5 /  BLD BLD BLD BLD BLD BLD BLD
7 WNV CCR5 /   4.1   1.1 3.2   0.6 2.9   0.5 4.3   0.5 0.3   0.05 12.6   1.8 24.9   0.5
7 WNV CCR5 /   2.9   0.9 3.6   0.9 3.2   0.7 4.9   0.8 0.3   0.09 11.2   3.2 22.6   1.8
12 WNV CCR5 /   4.8   0.6 0.3   0.06 0.4   0.1 3.6   0.4 0.2   0.05 8.2   0.9 22.5   0.7
12 WNV CCR5 /  2.5   0.7a 0.6   0.2 0.9   0.5 3.3   1.5 0.2   0.1 5.8   3.3 15.6   5.5
Data are pooled from two to three individual experiments with two to three mice in each group and are presented as the mean   SEM. Units are expressed as nanograms per 
gram of brain tissue.
aP   0.02 when compared to CCR5 /  mice at the same day after infection.
BLD; below the level of detection; DAI, days after infection.
Table II. Effect of CCR5 inactivation on induction of immunoregulatory factors in the brain by WNV
DAI Infection Strain IL-1  IL-4 IL-10 IFN-  IFN-  TNF-  ICAM-1 MMP-9 TIMP-1
7 mock CCR5 /  0.04   0.02 BLD BLD BLD BLD BLD 14.6   0.5 4.8   0.6 0.4   0.03
7 mock CCR5 /  0.2   0.02 BLD BLD BLD 0.07   0.01 BLD 10.6   0.3 4.1   0.4 0.4   0.04
7 WNV CCR5 /  0.3   0.01 BLD BLD 9.0   2.0 0.08   0.05 0.7   0.3 47.5   7.6 53.9   10.1 11.8   3.0
7 WNV CCR5 /  0.2   0.07 BLD BLD 6.0   2.1 0.14   0.08 0.3   0.2 41.1   7.3 28.9   7.6 10.9   3.2
12 WNV CCR5 /  0.3   0.08 BLD BLD 0.2   0.1 0.09   0.07 BLD 41.2   3.7 25.1   12.8  9.1   1.7
12 WNV CCR5 /  0.2   0.07 BLD BLD 0.1   0.07 0.06   0.05 BLD 29.5   8.5 12.5   4.2 1.3   0.01a
Data are pooled from two to three individual experiments with two to three mice in each group and are presented as the mean   SEM. Units are expressed as nanograms per 
gram of brain tissue.
aP   0.02 when compared to CCR5 /  mice at the same day after infection.
BLD; below the level of detection; DAI, days after infection.JEM VOL. 202, October 17, 2005 1093
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from WNV-infected CCR5 /  donors. WNV-infected
CCR5 /  mice that received CCR5 /  splenocytes had a
significantly greater amount of CD4  and CD8  T cells,
NK1.1  cells, and infiltrating macrophages (increased 2.3-,
5.3-, 3.1-, and 7.9-fold, respectively) compared with WNV-
infected CCR5 /  mice that received CCR5 /  spleno-
cytes (Fig. 5 D, P   0.02). In the CCR5 /  mice that re-
ceived CCR5 /  splenocytes, we were able to determine by
FACS that 4.7% of the CD4  T cells, 9.6% of CD8  T cells,
and 0.9% of NK1.1  cells in the brain expressed CCR5,
demonstrating that the transferred cells were able to migrate
to the brain.
CCR5 is critical to viral control and survival
We next tested the importance of CCR5 on viral clearance
and survival. Viral load in the spleens of CCR5 /  and
CCR5 /  mice was not statistically different in onset, magni-
tude, duration, or clearance as both groups had a maximal vi-
ral load on day 3 after infection and surviving mice had
cleared virus from the spleen by day 9 after infection (Fig. 6
A), further indicating that the immune response to WNV in
CCR5 /  mice is not altered. WNV-infected CCR5 / 
mice had nearly identical CNS viral loads as CCR5 /  con-
trols on day 7 after infection (Fig. 6 B). However, whereas
surviving WNV-infected CCR5 /  mice began to clear vi-
rus by day 12, the few surviving CCR5 /  mice available for
analysis showed no decrease in CNS viral load on day 12, but
rather a 32-fold increase relative to controls. This was evident
even when CCR5 /  mice were selected to match the poor
clinical status of CCR5 /  mice at this time point (Fig. 6 B).
Consistent with this result, infection with WNV was uni-
formly fatal in CCR5 /  mice (n   38), whereas in CCR5 / 
mice mortality was 35% (Fig. 6 C, n   50). All infected
CCR5 /  mice were dead by day 13. In contrast, WNV-
infection in mice lacking either CCR1 or CX3CR1, which
are two chemokine receptors related to CCR5 and shown
by RNA analysis (Fig. 1) to be up-regulated by WNV infec-
tion, resulted in mortality that was only slightly increased rel-
ative to that observed in wild-type control mice (Fig. 6 C).
Finally, adoptive transfer of splenocytes from WNV-infected
Figure 5. CCR5 deficiency affects immune responses to WNV 
selectively in the brain. (A) Serum cytokine analysis. The factor analyzed is 
identified at the bottom of the graph. Data were pooled from two experiments 
with five to seven mice in each group, and are presented as mean   SEM 
pg/ml serum as a function of time after infection. (B and C) Intracellular 
cytokine staining for WNV-induced IFN- . Splenocytes were isolated from 
mice at the indicated days after WNV infection and assayed without 
exogenous stimulation (B) or after 4 h of stimulation with ionomycin and 
PMA (C). Data presented are from one experiment with five mice at each 
time point. Values at the top of each bar are the percentage of total cells 
represented by the indicated cell type. (D) Adoptive transfer of CCR5 /  
and CCR5 /  splenocytes from WNV-infected mice into WNV-infected 
CCR5 /  mice. Infected CCR5 /  recipient mice, designated (WT → KO) and 
(KO → KO) received splenocytes from infected CCR5 /  or infected CCR5 /  
donor mice, respectively, 4 d after s.c. infection. FACS analysis was performed 
4 d after transfer (8 d after infection). Data are presented as the mean   
SEM and are from one experiment with five mice in each group. 
(B and C) Percents shown are the percentage of total cells. *, P   0.02 for the 
indicated comparison (of total cell number) by Student’s t test.CCR5 AND WEST NILE VIRUS PATHOGENESIS | Glass et al. 1094
CCR5 /  donor mice to WNV-infected CCR5 /  recipi-
ents (WT → KO) reduced mortality to the level observed for
wild-type C57BL/6 mice. In contrast, transfer of the same
number of splenocytes from WNV-infected CCR5 /  mice
to WNV-infected CCR5 /  recipients (KO → KO) had
only a minor protective effect (Fig. 6 D).
DISCUSSION
This study provides a detailed analysis of the molecular and
cellular immune response in the brain during WNV infec-
tion and demonstrates that expression of the chemokine re-
ceptor CCR5 is crucial for viral clearance and survival in a
mouse model of disease. WNV induced production of all
three CCR5 ligands in the brain, with particularly high and
durable induction of CCL5, which is consistent with local
accumulation of CCR5-expressing NK cells, macrophages,
and CD4  and CD8  T lymphocytes that we observed in
the model. Several lines of evidence lead us to believe that
trafficking of leukocytes expressing CCR5 to the WNV-
infected mouse brain is critical for survival. First, genetic dis-
ruption of CCR5 markedly reduced accumulation of these
cell types in brains of WNV-infected mice, without signifi-
cantly affecting CNS expression of other immunoregulatory
factors, including the CCR5 ligands CCL3, CCL4, and
CCL5. Second, there was no defect in clearance of the virus
from the spleen in CCR5 /  mice. Third, WNV-induced
production of IFN-  by CD4  and CD8  T cells in the
spleen was identical for CCR5 /  and CCR5 /  mice.
Fourth, when splenocytes from WNV-infected CCR5 / 
or CCR5 /  mice were adoptively transferred into WNV-
infected CCR5 /  mice, we found much greater leuko-
cyte accumulation in the brain after CCR5 /  than after
CCR5 /  cell transfer and detected CCR5  leukocytes in
Figure 6. West Nile virus infection is uniformly fatal in CCR5 
knockout mice. (A) Time course of viral clearance from spleen. Virus was 
quantified in the spleens of the indicated strains of surviving mice at the 
indicated times by focus formation assay. Mock-infected mice were analyzed 
on day 7 of the experiment. (B) Time course of viral clearance from brain. 
Virus was quantified in the brain of the indicated strains of mice at the 
indicated times by focus formation assay. Data were pooled from three to 
four experiments with three to five mice at each time point indicated and 
are presented as the mean   SEM. *, P   0.02 for the indicated comparison 
by Student’s t test. N/A, not applicable, because all infected CCR5 /  die by 
day 13. (C) Kaplan-Meier analysis of survival of WNV-infected mice. Results 
shown are pooled data from three independent experiments for CCR5 /  
mice (n   50 total mice) and CCR5 /  mice (n   34), and two independent 
experiments for CCR1 /  mice (n   30) and CX3CR1 /  mice (n   32). 
Similar results were obtained for both wild-type C57BL6/J and C57BL/6NTac 
control mice; however, only the C57BL6/J results are shown (CCR5 / ). 
(D) Kaplan-Meier analysis of survival of adoptive transfer mice. WT → KO, 
transfer of splenocytes from WNV-infected CCR5 /  mice into WNV-infected 
CCR5 /  mice; KO → KO, transfer of splenocytes from WNV-infected 
CCR5 /  mice to WNV-infected CCR5 /  mice. The following control 
groups were included that did not undergo adoptive transfer: Mock, 
mock-infected CCR5 / mice; CCR5 / , WNV-infected CCR5 /  mice; and 
CCR5 / , WNV-infected CCR5 /  mice. Data represent a single experiment 
with 10 mice in each group.JEM VOL. 202, October 17, 2005 1095
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the brains of CCR5 /  recipients. This experiment, which
involves direct injection of WNV-activated CCR5 /  or
CCR5 /  splenocytes into the blood, bypasses the splenic
egress step, and suggests strongly, when coupled with unal-
tered splenic T cell or viral clearance responses in CCR5 / 
mice, that CCR5 functions by promoting trafficking of leu-
kocytes from the blood to the brain in response to WNV
infection, for the purpose of containing and clearing the vi-
rus. This is consistent with previously published work on WNV
which demonstrated that RAG /  mice have dramatically
increased CNS viral burden and succumb to infection within
12 d, the same time frame that we found for CCR5 /  mice
(19). Furthermore, mice lacking CD8  T cells also have in-
creased viral burden in the CNS and mortality when in-
fected with WNV (13, 18, 23–25). Shirato et al. have re-
cently reported an increased expression of mRNA for
CCR5 ligands when mice were infected i.p. with a lethal
versus nonlethal strain of WNV (14). Our data confirm and
extend these results in a distinct model by providing mRNA
and protein analysis for these and numerous other immuno-
regulatory molecules and by directly testing the importance
and role of CCR5.
The critical role of CCR5 in WNV pathogenesis appears
to be unique compared with other neurotropic viruses that
have been tested to date. CNS infection with lymphocytic
choriomeningitis virus results in equivalent viral burden and
mortality in CCR5 /  and CCR5 /  mice suggesting that
this receptor does not play a role in pathogenesis in this model
(26). Likewise, infection with the neurovirulent retrovirus
FR98 results in identical mortality rates and CNS viral burden
in CCR5 /  and CCR5 /  mice (27). Infection with a neu-
rovirulent strain of mouse hepatitis virus (MHV) results in sim-
ilar viral titers in the CNS of CCR5 /  and CCR5 /  mice,
but knockouts have reduced demyelination, the major mani-
festation of disease in this model. The mechanism involves
CCR5-dependent recruitment of macrophages and CD4  and
CD8  T cells to the CNS (28). Thus, CCR5 promotes demy-
elinating disease in MHV infection, not antiviral host defense
as it does in WNV infection. CCR5 has also been demon-
strated to regulate leukocyte trafficking to the brain, but not
the lung, after Cryptococcus neoformans infection (29).
The importance of CCR5 also varies among noninfec-
tious, immunologically mediated, CNS disease. CCR5 defi-
ciency has no effect on experimental autoimmune encepha-
litis (EAE), despite the fact that CCR5 ligands are highly
expressed in the CNS of mice with EAE (30). In addition,
wild-type and CCR5-deficient mice have similar outcomes
in experimental autoimmune neuritis, including similar lev-
els of leukocytes recruited to the cauda equina (31). These
examples show the potential for chemokine receptors to play
specific and important roles or more redundant roles de-
pending on the disease context, and the spatial, temporal,
and quantitative details of cognate ligand expression.
Our data raise new questions regarding whether CCR5
may play a more general role in the immune response to
other flaviviruses. In this regard, in a recent study of 10 cy-
tokines in patients infected with Japanese Encephalitis virus
(the prototype flavivirus), increased serum CCL5 alone was
associated with a fatal outcome (32). The mechanism was
not established, but could conceivably involve desensitiza-
tion of leukocyte CCR5 in the bloodstream, thereby pre-
venting trafficking to the infected CNS.
We found that CCR1, CCR2, CXCR3, and CX3CR1
and their ligands were also up-regulated in mouse brains by
WNV. These systems could work cooperatively with CCR5
and could explain why leukocytes accumulate in small num-
bers in the CNS of WNV-infected CCR5 /  mice and why
many of the leukocytes in the WNV-infected brain are
CCR5 negative. Induction of CXCR3 was particularly
strong, and is consistent with induction of a Th1-polarized
cytokine response in the brain (18, 23, 24). However, our
results using knockout mice do not support an important,
nonredundant role for CCR1 or CX3CR1 in this model.
Our gene and protein expression data also suggest new and
testable hypotheses regarding the role in control of WNV
infection of TNF- , the IL-12/IFN-  axis, IFN- , the leu-
kocyte adhesion molecule ICAM-1, the matrix metallopro-
teinase MMP-9, and the metalloproteinase inhibitor TIMP-1
(33). WNV has been reported to be very sensitive to both
exogenous type I and II interferons in vitro (34), but they
are only able to prevent infection in vivo in mice when
given before challenge (35). IFN-  may be even less effec-
tive in humans because infection with WNV has been re-
ported in patients actively being treated with IFN-  and ri-
bavirin for hepatitis C (36). Matrix metalloproteinases may
be important in disrupting the blood brain barrier to allow
hematogenous spread of WNV to the CNS, as has been pre-
viously suggested (19). Although the role of TNF-  in the
brain is unclear, recent work has clarified its importance in
the periphery where it is produced in a TLR3-dependent
manner and mediates permeabilization of the blood brain
barrier to facilitate WNV entry (12). The specific roles in
pathogenesis of these and other factors induced in the brain
by WNV are currently under investigation.
An important question raised by our findings is
whether CCR5 is also protective in WNV infection of
humans. In limited studies, T cells and macrophages have
been reported to accumulate in WNV-infected human
brains as they do in our mouse model (25, 37). Moreover,
like humans, the mouse is easily infected with WNV, and
the major clinical manifestations of disease are similar in
both species: encephalitis and mortality in a subset of in-
fected individuals. If CCR5 is protective in humans, indi-
viduals homozygous for the CCR5 32 mutation, who
lack functional CCR5 and include 1% of North American
Caucasians (38), may be at greater risk for fatal encephalitis
from WNV infection. A related issue is the safety of
CCR5 blocking agents under development for patients
with HIV/AIDS who become infected with WNV.
In conclusion, our data identify CCR5 as a critical protec-
tive factor in fatal encephalitis caused by WNV in a mouse
model. The effect is highly specific relative to other neurotro-CCR5 AND WEST NILE VIRUS PATHOGENESIS | Glass et al. 1096
pic viruses and at least two other relevant chemokine recep-
tors. Loss of CCR5 results in decreased ability to recruit/
maintain leukocytes into the infected CNS where they may
function to clear the virus. The data also raise important new
questions about the potential roles of other immunoregulatory
systems that are induced by WNV in this model and in man.
MATERIALS AND METHODS
Mouse strains. Mouse studies were performed in an animal biosafety level
three facility under a protocol approved by the National Institute of Allergy
and Infectious Diseases/National Institutes of Health (NIH) Animal Care and
Use Committee. CCR5 /  mice (B6;129P2-Ccr5tm1Kuz), its approximate ge-
netic match mouse strain B6129PF2 and C57BL6/J mice were all purchased
from the Jackson Laboratory. Infection of B6129PF2 and C57BL6/J mice
with 104 ffu WNV induced similar changes and time courses with regard to
all parameters that were compared (mortality, CNS viral load, CNS accumu-
lation of leukocyte subsets [total and CCR5  T cells, NK cells, and macro-
phages], and CNS chemokine protein [CCL3, CCL4, CCL5, and CXCL10];
unpublished data). In all experiments shown, data for CCR5 /  mice were
generated using the C57BL6/J mouse. CX3CR1 /  mice (F10 backcross on
the C57BL/6NTac background), CCR1 /  mice (F10 backcross on the
C57BL/6NTac background), and control C57BL/6NTac mice were ob-
tained from Taconic. All experiments were initiated using female mice 8–12
wk old. Mice were selected randomly for phenotypic analysis at day 7 after
infection with WNV. On day 12 after WNV infection, all surviving
CCR5 /  mice were severely ill (limp tail, hunched back, ruffled fur, mini-
mal activity), and therefore infected C57BL6/J mice with similar clinical signs
were selected for phenotypic analysis at this time point.
Viral infections. WNV strain NY99-35262 was provided by R. Lanciotti
(Centers for Disease Control and Prevention, Fort Collins, CO). Originally
isolated from a Chilean flamingo at the Bronx Zoo in 1999 (3), this isolate
had been passaged once in Vero cell culture that contained 10% FBS. It was
then reamplified by two passages in Vero cells (WHO seed passage 143) that
did not contain FBS. A virus suspension was prepared that had a titer of 2  
107 ffu/ml, as determined using an immunostaining focus-forming assay and
WNV-specific mouse antibodies (39). Mice were injected s.c. in the back of
the neck with either 104 ffu WNV-NY99 suspended in 50  l HBSS (Invi-
trogen) or with HBSS alone (mock infected). Mice were monitored visually
and weighed daily. Brains of killed mice were aseptically removed, weighed
and placed directly in either 2 ml HBSS (for ELISA and viral titer assay) or
5 ml FACS buffer (HBSS   1% BSA   0.1% NaN3; Sigma-Aldrich).
ELISA. Brains were homogenized in sterile HBSS and frozen at  80 C.
Samples were thawed and centrifuged at 1,500 g for 25 min. The aqueous
fraction of the homogenate was serially diluted, and then analyzed for the
presence of specific cytokine and chemokine proteins using murine Quan-
tikine Immunoassay kits according to the manufacturer’s recommendations
(R&D systems). Samples were used only once.
RT-PCR. Total RNA was extracted from homogenized brain tissue using
TRIzol (Invitrogen). 2 ng of total RNA was converted to cDNA using a
Superscript III RT kit (Invitrogen), with random primers. PCR was per-
formed using 2  l cDNA in a reaction mix with Taq polymerase (Invitro-
gen). PCR reactions were optimized to determine the number of cycles
where the visual signal was in the linear range. These experiments deter-
mined that at  35 cycles, the signal plateaued for all targets tested. There-
fore, all PCR reactions were run for 30 cycles using the following primer
pairs:  -actin forward (5 -AGCCATGTACGTAGCCATCC-3 ),  -actin
reverse (5 -TCTCAGCTGTGGTGGTGAAG-3 ); CXCR3 forward
(5 -TGCTAGATGCCTCGGACTTT-3 ), CXCR3 reverse (5 -CGCT-
GACTCAGTAGCACAGC-3 ); CXCL4 forward (5 -AGTCCTGAGCT-
GCTGCTTCT-3 ), CXCL4 reverse (5 -GGCAAATTTTCCTCCCATTC-
3 ); CXCR4 forward (5 -TCAGTGGCTGACCTCCTCTT-3 ), CXCR4
reverse (5 -TTTCAGCCAGCAGTTTCCTT-3 ); CX3CL1 forward
(5 -AGCCCTGTGACATTTTCTGG-3 ), CX3CL1 reverse (5 -CCTC-
ACTCTCAGGAGCCAAC-3 ); and CX3CR1 forward (5 -GGAGAC-
TGGAGCCAACAGAG-3 ), CX3CR1 reverse (5 -TCTTGTCTGGCT-
GTGTCCTG-3 ). PCR products were separated and visualized on
ethidium bromide-stained 2% agarose/TBE gels.
Ribonuclease protection assay. Cytokine, chemokine, cytokine recep-
tor, and chemokine receptor mRNA transcripts were analyzed from total
brain RNA using mCK-1, mCK-5, mCR-1, and mCR-5 multi-template
probe sets, respectively (BD Biosciences). RPA analysis was performed us-
ing 10  g of total RNA using a previously described protocol (28). For
quantitation of signal intensity, autoradiographs were scanned and individ-
ual chemokine, cytokine, or chemokine/cytokine receptor transcript bands
were normalized as the ratio of band intensity to the GAPDH control.
Analysis was performed using NIH Image J1.32i software.
Cell isolation and FACS analysis. Mice were killed by cervical disloca-
tion. Organs were aseptically removed but not perfused before analysis. Sin-
gle cell suspensions of leukocytes were obtained from brain using a previ-
ously described method (40). In brief, brains were collected in FACS buffer
(HBSS   1% BSA   0.1% NaN3) and homogenized using the plunger por-
tion of a 6-cc syringe on ice in a petri dish. The suspension was brought to
7 ml with FACS buffer and 3 ml of 90% percoll in PBS was added. After 5
min at 22 C, the suspension was underlaid with 1 ml of 70% Percoll (in
RPMI), and was then centrifuged at 2,470 rpm for 20 min at 22 C at room
temperature. The leukocytes at the interphase were isolated and washed
three times in FACS buffer. Cells were fixed in 100  l BD Cytofix (BD
Biosciences) at 4 C for 20 min, counted using a hemacytometer, and then
filtered though a 70- m mesh screen. Cells were washed three times with
FACS buffer and incubated with Fc block (Becton Dickinson) in 100  l
CD16/32 Ab (BD Biosciences) diluted 1:200 in FACS buffer. Cells were
then incubated with specific antibodies for 45 min at 4 C, washed three
times and suspended in 400  l FACS buffer. Antibodies used for flow cy-
tometry were FITC-conjugated anti–mouse CD4 (GK1.5), CD19 (1D3),
CD45 (LCA, Ly-5; BD Biosciences) and F4/80 (Serotec); PE-conjugated
anti–mouse CCR5, NK1.1 (PK136), and CD45 (LCA, Ly-5); APC-conju-
gated anti-mouse CD8 (Ly-2) and NK1.1 (PK136; BD Biosciences); and
PerCP-conjugated anti-mouse CD4 (L3T4) and CD45 (LCA, Ly-5). In all
cases, an isotype-matched FITC-, PE-, APC-, or PerCP-conjugated anti-
body was used as the control. Cells were analyzed on a FACSCalibur (Bec-
ton Dickinson) where leukocytes were further refined by gating on cells
with the appropriate forward and side scatter profile. 100,000 events were
captured for analysis for each brain and each staining set. Data were ana-
lyzed using FlowJo software and are presented as the percentage of positive
cells within the gated population.
Intracellular cytokine staining. Mouse splenocytes (3   106 cells/well)
were incubated without exogenous stimulation for 4 h or with 50 ng/ml
PMA (Sigma-Aldrich) plus 500 ng/ml ionomycin (Sigma-Aldrich) for 4 h
at 37 C. Cells were then washed and blocked with Fc block for 20 min at
4 C. Cells were washed twice with FACS buffer, and surface markers were
stained with CD19-FITC, CD8-PE, and CD4-PerCP for 30 min at 4 C.
Cells were washed twice with FACS buffer and resuspended in 100  l
Cytofix/Cytoperm (Becton Dickinson) for 20 min at 4 C to permeabilize
the plasma membrane and facilitate antibody staining of IFN- . We washed
the cells twice with Perm/Wash solution and stained them with an APC-
conjugated mAb to mouse IFN-  (Becton Dickinson) for 30 min at 4 C.
Finally, cells were washed twice and resuspended in FACS buffer and ana-
lyzed on a FACSCalibur (Becton Dickinson). In all samples 100,000 events
were captured. Data were analyzed using FloJo software.
Adoptive transfer. CCR5 /  and CCR5 /  donor mice were infected
with 104 ffu WNV s.c. 3 d later, CCR5 /  recipient mice were infected
with 104 ffu WNV s.c. After recipients had been infected for 4 d, a durationJEM VOL. 202, October 17, 2005 1097
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sufficient for virus to enter the brain, 107 splenocytes from donors (infected
for 7 d at this time point) were transferred IV to recipients. Splenocytes
were isolated using lympholyte M (Cedarlane Labs). CCR5 /  recipients of
donor CCR5 /  splenocytes are referred to as KO → KO. CCR5 / 
recipients of donor CCR5 /  splenocytes are referred to as WT → KO.
Viral titers. Vero cells were maintained in OptiPro SFM (Invitrogen)
until passaged for the viral titer assay at which time they were grown in
OptiPro SFM   2% FBS   50  g/ml gentamicin. The virus was quanti-
tated by growth on confluent Vero cell monolayers in 12 well plates. 200
 l of brain homogenate supernatant was diluted in culture media and
placed on the cells in duplicate. Plates were incubated for 1 h at 37 C to
allow virus attachment, and then cells were overlaid with 2 ml of sterile
Opti-MEM (Invitrogen)   methyl cellulose 8 g/liter (EM Science)   2%
FBS   50  g/ml gentamicin. Plates were incubated for 2 d at 37 C, and
then washed three times with PBS (Biosource International) and incu-
bated for 1 h at 37 C with 500  l of diluted anti-WNV anti-sera/well
(HMAF; American Type Culture Collection VR-82). After washing,
samples were incubated at 37 C with 500  l of diluted anti–mouse/anti–
rabbit (1:10)-labeled polymer (DAKO Cytomation) for 1 h. After wash-
ing, 1 ml DAB mix (4.5 mg DAB [Sigma-Aldrich] /10 ml PBS   4.5  l
30% H202 [Fisher Scientific]/10 ml) was added at 22 C for 10 min to 1 h
to visualize WNV foci. The reaction was stopped by the addition of wa-
ter. The average of duplicate assays was used to determine viral titers,
which are expressed as ffu per gram of brain tissue.
Histology. Brains were aseptically removed from mice after cervical dis-
location and placed directly into 10% normal buffered formalin (Fisher
Chemicals) for 24 h. Samples were paraffin-embedded and cut into 6- m
sections (Histoserve). RNase protection (gloves, RNase-free water and
sterilized instruments) was used at all stages and slides were baked at 60 C
for 1 h after sectioning. Sections were stained with hematoxylin and eosin
(for visualization of cells) as well as luxol fast blue (for visualization of my-
elin). Separate sections were stained with an anti–human CD3 antibody
(DAKO Cytomation) or with hyperimmune mouse ascites fluid collected
after inoculation with WNV (HMAF). In brief, slides were deparaffinized
with Citrosolve (National Diagnostics) and graded ethanol followed by a
water wash. Slides were heated to 90 C and washed with water twice,
blocked with hydrogen peroxide for 10 min, and washed in water. Slides
were blocked with BSA for 20 min, and then incubated with primary an-
tibody overnight at a 1:100 dilution. Next, we washed the slides, incu-
bated them with biotinylated secondary antibody for 30 min at 1:500 di-
lution, and then rewashed. Slides were incubated with streptavidin for 30
min and washed and developed with DAB (DAKO Cytomation). Finally,
slides were counterstained with hematoxylin and dehydrated with graded
ethanol and Citrosolve.
Statistical analysis. Statistically significant differences between groups of
mice were determined by Student’s t test using Microsoft Excel MAC v.X
software, and p-values  0.05 were considered significant.
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